MRE for Diagnosis of Pancreatic Masses

Launched by YU SHI · Jul 27, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called Magnetic Resonance Elastography (MRE) to help diagnose pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC), which is a very aggressive type of cancer with a low survival rate. The trial aims to see if MRE can provide important information about the stiffness of pancreatic tissues, which may help doctors predict how the cancer will behave and guide treatment decisions.

To participate in this trial, you must be at least 18 years old, have a confirmed diagnosis of PDAC from a biopsy, and not have any other cancers outside the pancreas. Additionally, you should not have had any procedures that drain bile from the pancreas before surgery. If you join the study, you’ll undergo MRE imaging, which is a non-invasive test, meaning it doesn't require any surgery or needles. The trial is currently recruiting participants, and you will need to provide your consent to join. This research could lead to better ways to diagnose and treat pancreatic cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. granting of written informed consent
• • 2. age ≥18 years
• • 3. no history of extrapancreatic malignancy
• • 4. no preoperative biliary drainage
• • 5. definitive histologic evidence of PDAC in excisional biopsy
• • 6. with no less than three months of postoperative mortality or six months of follow- up
• Exclusion Criteria:
• • 1. inability to re-review of tissue specimens
• • 2. unacceptable estimates of MRE parameters, specifically invalid wave data during postprocessing, inconsistent breath-holdings, intolerable pain, and MRE hardware disconnection
• • 3. tumor diameters \<1.0 cm
• • 4. withdrawal/dropout during follow-up